A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial

OBJECTIVES: SARS-CoV2 infection leads to a concomitant pulmonary inflammation. This inflammation is supposed to be the main driver in the pathogenesis of lung failure (Acute Respiratory Distress Syndrome) in COVID-19. Objective of this study is to evaluate the efficacy and safety of a single dose tr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Trials
Main Authors: Rilinger, Jonathan, Kern, Winfried V., Duerschmied, Daniel, Supady, Alexander, Bode, Christoph, Staudacher, Dawid L., Wengenmayer, Tobias
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2020
Teme:
Letter
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7267747/
https://ncbi.nlm.nih.gov/pubmed/32493514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-020-04447-3
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki